Douglas S. Lehrer
About
Douglas S. Lehrer is a scholar working on Psychiatry and Mental health, Cognitive Neuroscience and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Douglas S. Lehrer has authored 24 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Psychiatry and Mental health, 11 papers in Cognitive Neuroscience and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Douglas S. Lehrer's work include Schizophrenia research and treatment (12 papers), Functional Brain Connectivity Studies (9 papers) and Vitamin D Research Studies (5 papers). Douglas S. Lehrer is often cited by papers focused on Schizophrenia research and treatment (12 papers), Functional Brain Connectivity Studies (9 papers) and Vitamin D Research Studies (5 papers). Douglas S. Lehrer collaborates with scholars based in United States, Canada and United Kingdom. Douglas S. Lehrer's co-authors include P.F. Buckley, David Castle, Brian J. Miller, Monte S. Buchsbaum, Bradley T. Christian, Jogeshwar Mukherjee, Eileen Kemether, Joseph Mantil, Douglas Mossman and Bingzhi Shi and has published in prestigious journals such as NeuroImage, American Journal of Psychiatry and Biological Psychiatry.
In The Last Decade
Douglas S. Lehrer
24 papers receiving 1.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Douglas S. Lehrer United States | 14 | 688 | 335 | 329 | 201 | 163 | 24 | 1.3k | ||
| Lena Flyckt Sweden | 20 | 608 0.9× | 242 0.7× | 293 0.9× | 106 0.5× | 226 1.4× | 50 | 1.2k | ||
| Franck Schürhoff France | 24 | 1.0k 1.5× | 488 1.5× | 358 1.1× | 200 1.0× | 182 1.1× | 68 | 1.8k | ||
| Vasilis P. Bozikas Greece | 23 | 931 1.4× | 446 1.3× | 345 1.0× | 278 1.4× | 108 0.7× | 73 | 1.6k | ||
| Heather Taylor United Kingdom | 19 | 685 1.0× | 367 1.1× | 461 1.4× | 176 0.9× | 72 0.4× | 34 | 1.5k | ||
| Scott W Woods United States | 11 | 536 0.8× | 249 0.7× | 224 0.7× | 214 1.1× | 153 0.9× | 17 | 964 | ||
| Neeraj Tandon United States | 26 | 867 1.3× | 641 1.9× | 244 0.7× | 200 1.0× | 149 0.9× | 44 | 1.6k | ||
| Lou Ann McAdams United States | 19 | 752 1.1× | 545 1.6× | 213 0.6× | 172 0.9× | 98 0.6× | 27 | 1.5k | ||
| Cherise Rosen United States | 26 | 1.1k 1.6× | 544 1.6× | 429 1.3× | 231 1.1× | 86 0.5× | 70 | 2.1k | ||
| Montserrat Graell Spain | 29 | 1.3k 1.8× | 418 1.2× | 806 2.4× | 138 0.7× | 82 0.5× | 79 | 2.0k | ||
| Avi Reichenberg United States | 14 | 605 0.9× | 320 1.0× | 234 0.7× | 227 1.1× | 188 1.2× | 28 | 1.3k |
Countries citing papers authored by Douglas S. Lehrer
Since
Specialization
Citations
This map shows the geographic impact of Douglas S. Lehrer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas S. Lehrer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas S. Lehrer more than expected).
Fields of papers citing papers by Douglas S. Lehrer
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Douglas S. Lehrer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas S. Lehrer. The network helps show where Douglas S. Lehrer may publish in the future.
Co-authorship network of co-authors of Douglas S. Lehrer
This figure shows the co-authorship network connecting the top 25 collaborators of Douglas S. Lehrer. A scholar is included among the top collaborators of Douglas S. Lehrer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas S. Lehrer. Douglas S. Lehrer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lehrer, Douglas S., et al.. (2023). Normal 24-hour urine calcium concentrations after long-term daily oral intake of vitamin D in doses ranging from 5000 to 50,000 international units in 14 adult hospitalized psychiatric patients. The Journal of Steroid Biochemistry and Molecular Biology. 231. 106329–106329.
2.
Mitelman, Serge A., Monte S. Buchsbaum, Nora S. Vyas, et al.. (2021). Reading abilities and dopamine D2/D3 receptor availability: An inverted U-shaped association in subjects with schizophrenia. Brain and Language. 223. 105046–105046.
3.
Lehrer, Douglas S., et al.. (2021). Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications. Nutrients. 13(5). 1511–1511.
4.
Buchsbaum, Monte S., Serge A. Mitelman, Bradley T. Christian, et al.. (2021). Four-modality imaging of unmedicated subjects with schizophrenia: 18F-fluorodeoxyglucose and 18F-fallypride PET, diffusion tensor imaging, and MRI. Psychiatry Research Neuroimaging. 320. 111428–111428.
5.
Mitelman, Serge A., Monte S. Buchsbaum, Bradley T. Christian, et al.. (2020). Relationship between white matter glucose metabolism and fractional anisotropy in healthy and schizophrenia subjects. Psychiatry Research Neuroimaging. 299. 111060–111060.
6.
Mitelman, Serge A., Monte S. Buchsbaum, Bradley T. Christian, et al.. (2019). Positive association between cerebral grey matter metabolism and dopamine D 2 /D 3 receptor availability in healthy and schizophrenia subjects: An 18 F-fluorodeoxyglucose and 18 F-fallypride positron emission tomography study. The World Journal of Biological Psychiatry. 21(5). 368–382.
7.
Lehrer, Douglas S., et al.. (2019). Daily oral dosing of vitamin D3 using 5000 TO 50,000 international units a day in long-term hospitalized patients: Insights from a seven year experience. The Journal of Steroid Biochemistry and Molecular Biology. 189. 228–239.
8.
Vyas, Nora S., Monte S. Buchsbaum, Douglas S. Lehrer, et al.. (2017). D2/D3 dopamine receptor binding with [F-18]fallypride correlates of executive function in medication-naïve patients with schizophrenia. Schizophrenia Research. 192. 442–456.
9.
Vyas, Nora S., Douglas S. Lehrer, Brian Merrill, et al.. (2017). 283. D2/D3 Dopamine Receptor Binding with [F-18] Fallypride Correlates of Executive Function in Medication-Naïve Patients with Schizophrenia. Biological Psychiatry. 81(10). S116–S117.
10.
Nahhas, Ramzi W., et al.. (2017). Comparing Global Assessment of Functioning (GAF) and World Health Organization Disability Assessment Schedule (WHODAS) 2.0 in schizophrenia. Psychiatry Research. 259. 251–253.
11.
Lehrer, Douglas S., et al.. (2017). Vitamin D, cod liver oil, sunshine, and phototherapy: Safe, effective and forgotten tools for treating and curing tuberculosis infections — A comprehensive review. The Journal of Steroid Biochemistry and Molecular Biology. 177. 21–29.
12.
Fontanella, Cynthia A., John V. Campo, Gary Phillips, et al.. (2016). Benzodiazepine Use and Risk of Mortality Among Patients With Schizophrenia. The Journal of Clinical Psychiatry. 77(5). 661–667.
13.
Lehrer, Douglas S., Michele T. Pato, Ramzi W. Nahhas, et al.. (2015). Paternal age effect: Replication in schizophrenia with intriguing dissociation between bipolar with and without psychosis. American Journal of Medical Genetics Part B Neuropsychiatric Genetics. 171(4). 495–505.
14.
Lehrer, Douglas S., Bradley T. Christian, Cemil Kirbas, et al.. (2010). 18F-Fallypride binding potential in patients with schizophrenia compared to healthy controls. Schizophrenia Research. 122(1-3). 43–52.
15.
Mossman, Douglas, Michael D. Bowen, David J. Vanness, et al.. (2009). Quantifying the accuracy of forensic examiners in the absence of a “gold standard”.. Law and Human Behavior. 34(5). 402–417.
16.
Buckley, P.F., Brian J. Miller, Douglas S. Lehrer, & David Castle. (2008). Psychiatric Comorbidities and Schizophrenia. Schizophrenia Bulletin. 35(2). 383–402.
17.
Christian, Bradley T., Douglas S. Lehrer, Bingzhi Shi, et al.. (2006). Measuring dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release during a spatial attention task. NeuroImage. 31(1). 139–152.
18.
Buchsbaum, Monte S., Brad T. Christian, Douglas S. Lehrer, et al.. (2006). D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophrenia Research. 85(1-3). 232–244.
19.
Lehrer, Douglas S., Bradley T. Christian, Joseph Mantil, et al.. (2005). Thalamic and Prefrontal FDG Uptake in Never Medicated Patients With Schizophrenia. American Journal of Psychiatry. 162(5). 931–938.
20.
Mossman, Douglas & Douglas S. Lehrer. (2000). Conventional and Atypical Antipsychotics and the Evolving Standard of Care. Psychiatric Services. 51(12). 1528–1535.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Lena Flyckt Breakdown of academic impact, for papers by Franck Schürhoff Breakdown of academic impact, for papers by Vasilis P. Bozikas Breakdown of academic impact, for papers by Heather Taylor Breakdown of academic impact, for papers by Scott W Woods Breakdown of academic impact, for papers by Neeraj Tandon Breakdown of academic impact, for papers by Lou Ann McAdams Breakdown of academic impact, for papers by Cherise Rosen Breakdown of academic impact, for papers by Montserrat Graell Breakdown of academic impact, for papers by Avi Reichenberg